Ridgecrest Retirement & Healthcare v. Urban

135 S.W.3d 757, 2004 WL 35935
CourtCourt of Appeals of Texas
DecidedFebruary 6, 2004
Docket01-02-00663-CV
StatusPublished
Cited by9 cases

This text of 135 S.W.3d 757 (Ridgecrest Retirement & Healthcare v. Urban) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ridgecrest Retirement & Healthcare v. Urban, 135 S.W.3d 757, 2004 WL 35935 (Tex. Ct. App. 2004).

Opinion

OPINION

ADELE HEDGES, Justice (Assigned).

Plaintiffs/appellees, Darlyn Jill Urban, individually, and as representative of the estate of Donald G. Maker, and Richard J. Maker, individually, sued defendant/appellant, Ridgecrest Retirement & Healthcare d/b/a Ridgecrest Retirement Center, Ltd. (“Ridgecrest”), for negligence in its care of Donald G. Maker (“Maker”). A jury returned a verdict awarding $999,999.99 to Maker’s estate, but found that his children sustained no damages. The trial court entered judgment against Ridgecrest and in favor of Maker’s estate in the amount of $999,999.99, plus prejudgment interest of $169,191.71. We reverse and remand.

Background

Maker was a resident of Ridgecrest, an assisted living facility, since 1995. Before his admission to Ridgecrest, Maker had a multitude of health problems, including three prior strokes, diabetes, atrial fibrillation, and hypertension. He was in a wheel *759 chair because of paralysis in his right arm and leg.

Because of the atrial fibrillation, Maker was at risk for blood clots. His doctor, Dr. Jensen, prescribed Coumadin, a blood-thinner medication, to reduce the risk of another stroke. Coumadin is an anticoagulant that helps prevent clots from forming and leading to strokes. A test known as Protime monitors the level of Couma-din. A low Coumadin level indicates a risk of stroke; a high level indicates a risk of bleeding problems.

In early July 1998, Maker developed a urinary tract infection. Dr. Jensen prescribed the antibiotic Bactrim, which did not cure the infection. On July 27, 1998, Maker continued to have problems with bowel incontinence. Dr. Jensen changed the antibiotic prescription to Cipro, which had the side effect of thinning blood. Dr. Jensen was aware that Cipro had an “enhancement” effect on the Coumadin to thin Maker’s blood even further. On July 27, Dr. Jensen ordered a Protime test to be run by Thursday, July 30.

The procedures for ordering lab work were as follows: Maker (or whoever took him to the doctor) would bring the doctor’s order to Ridgecrest. Ridgecrest would then write that order into a lab book supplied by Physicians’ Reference Laboratories (“PRL”). As a courtesy to residents, so that they would not have to go to the lab, Ridgecrest made arrangements for PRL to come to Ridgecrest and take blood and urine samples from the residents. PRL would come to Ridgecrest, review the order in the lab book, obtain the specimens needed to run the ordered tests, and fax a copy of the lab result to Ridgecrest.

Prior to this lawsuit being filed, PRL’s lab book disappeared. PRL admitted that one of its former employees took the lab book. It is unknown why Maker’s Protime test, which Dr. Jensen ordered to be run on July 30, was not run until July 31. PRL performed Maker’s Protime test on Friday, July 31, at 5:00 a.m.

A normal blood clotting time is 13-15 seconds. Maker’s Protime test indicated that his time was 36.4 seconds, which is abnormal. Maker’s results were faxed to Ridgecrest on Friday, July 31, at 11:58 p.m., two minutes before midnight. The room where Ridgecrest kept the fax machine was closed at 5 p.m. on Friday for the remainder of the weekend. Ridge-crest contends that PRL should have faxed the lab result to Maker’s physician because Ridgecrest did not, and was not required to, have individuals on staff who were trained to interpret lab results.

After the weekend, on Monday, August 3, a Ridgecrest medication aide, Edith Dukes, saw Maker’s abnormal lab report. She faxed the results to Dr. Jensen at 8:29 a.m. that morning. Upon receipt of the abnormal result, Dr. Jensen instructed Ridgecrest to stop administering the Coumadin to Maker and inject vitamin K, which is designed to thicken the blood. Dr. Jensen did not request that Ridgecrest bring Maker to the hospital. He expected that Maker’s Protime result would return to normal within one or two days.

Pursuant to Dr. Jensen’s orders, Maker did not receive any more Coumadin and instead received the vitamin K injection. Ms. Owenby, the director of assisted living at Ridgecrest, testified that Maker was fine on August 3. He did not appear to be bleeding, dizzy, confused, or disoriented.

In the early morning of Tuesday, August 4, Maker was found on the floor. He was incontinent of urine and bowel. Later that morning, Maker began to experience difficulty breathing. Ridgecrest called Maker’s son and Dr. Jensen, who ordered him transferred to the hospital. The emergency room assessed Maker’s condition as non-urgent. The emergency room records indicate that Maker denied being in any *760 pain. At the time of his admission, Maker’s blood pressure was adequate. At 3:30 p.m., he was given a blood transfusion. That evening on Tuesday, August 4, at approximately 7:55 p.m., Maker died.

The cause of death listed on Maker’s death certifícate was “CVA,” or cerebro-vascular accident or stroke. Dr. Jensen agreed with the cause of death, opining that Maker did not begin bleeding until the morning of Tuesday, August 4. Dr. Krouse, one of Maker’s experts, disagreed, and instead opined that Maker bled to death. Dr. Krouse testified that Maker had an overdose of Coumadin from July 31 to August 4, which resulted in Maker bleeding internally for a few days before his admission to the hospital.

Procedural History

Maker’s children, individually and as representatives of Maker’s estate, sued Ridgecrest and PRL for negligence. Rid-gecrest filed a cross action against PRL for contribution. The allegations of negligence were that Ridgecrest did not have lab work performed in a timely fashion, did not forward an abnormal test result to Maker’s physician, and violated multiple provisions of the Texas Administrative Code pertaining to assisted living facilities. Ridgecrest’s claim against PRL for contribution was based on an agreement and PRL’s course of performance to forward lab results directly to the residents’ physicians.

Before the introduction of any evidence, plaintiffs announced that they had settled with PRL and dropped all claims against PRL. The trial court proceeded with plaintiffs’ claims against Ridgecrest, and Ridge-crest continued to maintain its cross action against PRL. The jury returned a verdict awarding $999,999.99 to Maker’s estate and no damages to Maker’s children. The jury allocated 100% of the fault against Ridgecrest and none against PRL. The trial court entered judgment against Rid-gecrest and in favor of Maker’s estate in the amount of $999,999.99, plus prejudgment interest of $169,191.71. The court denied recovery to Maker’s children in their individual capacities and denied Rid-gecrest’s claim for contribution from PRL.

In nine issues, Ridgecrest contends as follows: (1) the trial court erred in excluding Defense Exhibit 2 because it established that PRL had a policy to fax lab results directly to residents’ physicians; (2) the trial court erred in excluding the testimony of Ms. Huntsman, a Ridgecrest administrator, and in granting a limiting instruction regarding her testimony; (3) Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
135 S.W.3d 757, 2004 WL 35935, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ridgecrest-retirement-healthcare-v-urban-texapp-2004.